Budget impact and cost-effectiveness analyses of the COBRA-BPS multicomponent hypertension management programme in rural communities in Bangladesh, Pakistan, and Sri Lanka. by Finkelstein, Eric A et al.
Articles
www.thelancet.com/lancetgh   Vol 9   May 2021 e660
Budget impact and cost-effectiveness analyses of the 
COBRA-BPS multicomponent hypertension management 
programme in rural communities in Bangladesh, Pakistan, 
and Sri Lanka
Eric A Finkelstein*, Anirudh Krishnan†, Aliya Naheed†, Imtiaz Jehan†, H Asita de Silva†, Mihir Gandhi, Ching Wee Lim, Nantu Chakma, 
Dileepa S Ediriweera, Jehanzeb Khan, Anuradhani Kasturiratne, Samina Hirani, A K M Solayman, Tazeen H Jafar*, COBRA-BPS study group‡
Summary
Background COBRA-BPS (Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka), a multi-
component hypertension management programme that is led by community health workers, has been shown to be 
efficacious at reducing systolic blood pressure in rural communities in Bangladesh, Pakistan, and Sri Lanka. In this 
study, we aimed to assess the budget required to scale up the programme and the incremental cost-effectiveness 
ratios.
Methods In a cluster-randomised trial of COBRA-BPS, individuals aged 40 years or older with hypertension who lived 
in 30 rural communities in Bangladesh, Pakistan, and Sri Lanka were deemed eligible for inclusion. Costs were 
quantified prospectively at baseline and during 2 years of the trial. All costs, including labour, rental, materials and 
supplies, and contracted services were recorded, stratified by programme activity. Incremental costs of scaling up 
COBRA-BPS to all eligible adults in areas covered by community health workers were estimated from the health 
ministry (public payer) perspective.
Findings Between April 1, 2016, and Feb 28, 2017, 11 510 individuals were screened and 2645 were enrolled and 
included in the study. Participants were examined between May 8, 2016, and March 31, 2019. The first-year 
per-participant costs for COBRA-BPS were US$10·65 for Bangladesh, $10·25 for Pakistan, and $6·42 for Sri Lanka. 
Per-capita costs were $0·63 for Bangladesh, $0·29 for Pakistan, and $1·03 for Sri Lanka. Incremental cost-effectiveness 
ratios were $3430 for Bangladesh, $2270 for Pakistan, and $4080 for Sri Lanka, per cardiovascular disability-adjusted 
life year averted, which showed COBRA-BPS to be cost-effective in all three countries relative to the WHO-CHOICE 
threshold of three times gross domestic product per capita in each country. Using this threshold, the cost-effectiveness 
acceptability curves predicted that the probability of COBRA-BPS being cost-effective is 79·3% in Bangladesh, 
85·2% in Pakistan, and 99·8% in Sri Lanka.
Interpretation The low cost of scale-up and the cost-effectiveness of COBRA-BPS suggest that this programme is a 
viable strategy for responding to the growing cardiovascular disease epidemic in rural communities in low-income 
and middle-income countries where community health workers are present, and that it should qualify as a priority 
intervention across rural settings in south Asia and in other countries with similar demographics and health systems 
to those examined in this study.
Funding The UK Department of Health and Social Care, the UK Department for International Development, the 
Global Challenges Research Fund, the UK Medical Research Council, Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Cardiovascular diseases are the leading cause of death 
worldwide.1 Cardiovascular diseases are particularly 
lethal in rural areas in low-income and middle-income 
countries where health systems are weakest and the case 
fatality rates of cardiovascular diseases are highest.2–5 
Addressing this burden requires low-cost, scalable 
interventions that target prevention and treatment of 
hypertension, and other cardiovascular disease risk 
factors.6–9
In 2020, we reported the efficacy of a cluster-
randomised controlled trial, Control of Blood Pressure 
and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka 
(COBRA-BPS), in rural communities in three south-
Asian countries (Bangladesh, Pakistan, and Sri Lanka).10 
We showed that this contextually relevant, multi-
component intervention delivered by community health 
workers (CHWs) was efficacious at reducing systolic 
blood pressure.10 At 24-month follow-up, the decline 
in systolic blood pressure across the three countries 
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was 5·2 (95% CI 3·2–7·1) mm Hg greater in the COBRA-
BPS cluster than in control clusters, with consistent 
effects within each country.
In the present study, we report the budget impact 
analysis and cost-effectiveness of a national scale-up to 
rural areas within each country where CHWs are present. 
The budget impact analysis allows policy makers to 
budget the immediate and future costs should COBRA-
BPS be scaled up beyond the trial communities. The 
cost-effectiveness analysis facilitates the comparison of 
COBRA-BPS with other interventions and helps to 
establish whether the programme represents good value 
for money.
Methods
Study design and participants
We did a cluster-randomised controlled trial in 30 rural 
com munities in Bangladesh, Pakistan, and Sri Lanka. 
These 30 communities were randomly assigned to 
receive either COBRA-BPS or usual care, stratified by 
country (ten clusters each) and distance from the 
government clinic (near [≤2 km] or far [>2 km]). 
Individuals aged 40 years or older with hypertension 
were eligible for inclusion in the study. The primary and 
secondary outcome results of that cluster-randomised 
trial were reported in 2020.10
Ethics approval for the study was obtained from the 
institutional review boards of the National University of 
Singapore, the Interventions Research Ethics Committee 
of the London School of Hygiene & Tropical Medicine, 
and institutions of each participating country (the 
International Centre for Diarrhoeal Disease Research in 
Bangladesh, the Aga Khan University in Pakistan, and 
the University of Kelaniya in Sri Lanka).
Multicomponent intervention
COBRA-BPS was comprised of the following five 
components: (1) home health education by government 
CHWs, (2) blood pressure monitoring and referral, 
(3) training of public and private providers in management 
of hypertension, (4) designated hypertension triage 
counter and care coordinators in government clinics, and 
(5) a financing model to compensate for additional 
services equivalent to 20% of the salary of CHWs. The 
money was channelled through the district health office 
and offered the flexibility to hire additional staff or expand 
the role of existing staff but with the expectation that 
COBRA-BPS would not compromise delivery of existing 
services. Travel subsidies were allocated to low-income 
participants via means testing.
Usual care
Usual care comprised of existing community services, 
with CHWs routinely visiting homes for maternal and 
child care only. The clinics did not have hypertension-
related triage counters or care coordinators.
Screening, recruitment, and follow-up 
Trained research staff visited all households in the study 
clusters and obtained written informed consent from 
Research in context
Evidence before this study
The biomedical and health economics literature was reviewed 
to identify studies in which the burden of hypertension and 
cardiovascular diseases and economic evaluation of 
interventions was reported, particularly from low-income and 
middle-income countries. PubMed and Google Scholar 
databases were searched for studies or abstracts published in 
English between Jan 1, 1970, and April 20, 2020, using the 
search terms “cost-effectiveness”, “blood pressure”, “low-
income countries”, “middle-income countries”, “hypertension”, 
and “south Asia”. The relevant full-text articles were selected 
and searched for further information and material. Although 
there have been budget impact and cost-effectiveness analyses 
on hypertension trials with interventions led by community 
health workers in low-income and middle-income countries, 
most of these trials focused on urban areas or on a single 
country. The lack of evidence from rural areas in multiple 
countries with differing health systems thus presents a barrier 
for broad implementation.
Added value of this study
To our knowledge, this study is the first budget impact and 
cost-effectiveness analysis on a scalable, community-based, 
multicomponent intervention that is led by community health 
workers in rural communities across three countries, namely 
Bangladesh, Pakistan, and Sri Lanka. We show that, compared 
with existing care, the Control of Blood Pressure and Risk 
Attenuation-Bangladesh, Pakistan, Sri Lanka (COBRA-BPS) 
programme is a cost-effective and scalable solution for 
controlling blood pressure among individuals with 
hypertension in rural areas in the three countries. The first-year 
per-participant costs for scaling up COBRA-BPS were 
US$10·65 for Bangladesh, $10·25 for Pakistan, and $6·42 for 
Sri Lanka. Per-capita costs (total costs divided by total national 
population count) were $0·63 for Bangladesh, $0·29 for 
Pakistan, and $1·03 for Sri Lanka. Incremental cost-
effectiveness ratios were $3430 for Bangladesh, $2270 for 
Pakistan, and $4080 for Sri Lanka per disability-adjusted life-
year averted.
Implications of all the available evidence
Our findings underscore that the COBRA-BPS multicomponent 
intervention presents a viable strategy to respond to the 
growing cardiovascular disease epidemic in low-income and 
middle-income countries and should qualify as a priority 
intervention.
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adults aged 40 years or older, who were then screened for 
eligibility. Follow-up was done with home visits every 
6 months for up to 2 years from baseline. Details of our 
delivery approach and outcomes are available in the 
study protocol and publication of results.10,11
Costs, assumptions, and budget impact analysis
We quantified all costs relating to components of 
COBRA-BPS, namely: (1) administration and oversight, 
(2) training of CHWs in blood pressure monitoring 
and home health education, (3) training of general 
practitioners, (4) implementation of home-based blood 
pressure monitoring and home health education, 
(5) coordination at hypertension triage counters, 
(6) medical visits (including travel subsidies and costs for 
additional medications), and (7) coordinating activities of 
CHWs’ supervisors. Data that captured all costs of labour, 
rental, materials and supplies, and contracted services 
incurred by these health-care services were collected 
prospectively during the trial. The cost components for 
each activity are detailed in the appendix (pp 4, 5). All 
costs tracking approaches and conversions are also 
described in the appendix (pp 5, 6).
Both the cost-effectiveness analysis and budget impact 
analysis assumed that COBRA-BPS would be scaled up 
with existing CHWs, and that the programme would be 
able to reach all rural households within the first year of 
the scale-up. For the budget impact analysis, we estimated 
the incremental cost of scaling up COBRA-BPS to all 
eligible adults aged 40 years or older in areas where 
CHWs are present (100% of the rural communities in 
Bangladesh and Sri Lanka and 60% of the rural 
communities in Pakistan) from the health ministry 
(public sector) perspective. Costs for the budget impact 
analysis are presented for the first 3 years of the scale-up 
on the basis of recommended practices.12–14 For the cost-
effectiveness analysis, consistent with how decisions are 
made by many countries,15 we estimated the lifetime 
incremental cost from the health system perspective, 
including both public and private sector costs.
Within-trial differences in health-care utilisation were 
estimated as for the primary effectiveness analysis using 
self-reported utilisation data captured from participants at 
baseline and at 24 months. Results of the utilisation 
analysis (as seen in the appendix pp 11, 12) revealed that 
the only consistent (across sites) and significant difference 
resulting from COBRA-BPS concerned greater use of 
antihypertensive medications in the COBRA-BPS group 
than the usual care group. Therefore, these costs are 
included in the cost-effectiveness analysis. They are 
not included in the budget impact analysis for Bangladesh 
or Pakistan because the public sector does not pay for 
antihypertension medications in these countries. In 
Sri Lanka, COBRA-BPS data show that 63% of all clinic 
visits at follow-up occurred at government facilities; 
therefore, we assume that 63% of antihypertension 
medication costs are paid by the government. When 
forecasting future costs, we assume a medication 
adherence rate of 75% that is maintained until death.16
Quantifying total costs for the budget impact analysis 
requires estimating both unit costs and the number of 
people expected to receive COBRA-BPS. To estimate the 
number expected to receive COBRA-BPS in year 1 of 
scale-up from the baseline, we multiplied estimates of 
the rural population aged 40 years or older in each 
country17 by estimates of hypertension prevalence 
obtained during screening visits within our trial sites. 
In subsequent years, cases were quantified on the basis 
of an estimated hypertension incidence rate of 8·26%, 
assuming an annual national population growth of 
1·0% in Bangladesh, 2·0% in Pakistan, and 1·1% in 
Sri Lanka.17,18 Additional details of our cost estimation 
approach, including the source data and assumptions 
used to generate the cost estimates, are presented in the 
appendix (pp 5, 6).
Cost-effectiveness analysis
The cost-effectiveness analysis is done over a lifetime as 
benefits of COBRA-BPS are expected to last indefinitely, 
but the analysis is limited to the cohort of people with 
hypertension identified at baseline. The numerator of the 
cost-effectiveness ratio is the incremental net cost in the 
first year of scale-up plus the present value of costs in 
subsequent years discounted at 3% per annum.19
For the cost-effectiveness analysis, the primary measure 
was prespecified as the cost per projected disability-
adjusted life-year (DALY) due to cardiovascular diseases 
that have been averted. Previous literature shows a linear 
association between blood pressure reduction and 
percentage reduction in mortality risk due to coronary 
heart disease, stroke, and cardiovascular diseases, and 
reveals that a sustained reduction of 10 mm Hg in systolic 
blood pressure results in a roughly 22% reduction in 
coronary heart disease events and a 41% reduction in 
stroke events and mortality.20 On the basis of these 
statistics, we followed a model presented in previous 
literature,21,22 and con servatively assumed that every 
1 mm Hg reduction in systolic blood pressure translates 
into a 2·2% reduction in cardiovascular disease DALYs 
and assumed that participants maintain the blood 
pressure reductions throughout their lifetime.
Converting the percentage reduction in DALYs into 
absolute values of cardiovascular disease DALYs requires 
estimating how many cardiovascular disease DALYs 
would occur in the absence of COBRA-BPS. The national 
level of cardiovascular disease DALYs was obtained from 
the Global Burden of Disease 2017 and adjusted by the 
percentage of the population that resides in rural areas.1,17 
This value was then multiplied by the percentage 
reduction in cardiovascular disease DALYs conferred by 
COBRA-BPS, to estimate the total cardiovascular disease 
DALY reduction.
To account for uncertainty in our assumptions on the 
underlying cost distribution or the exact association 
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between systolic blood pressure reductions and DALY 
improvements, we report scenario analyses focusing on 
three crucial parameters. These parameters are: (1) the 
highest incremental cost per capita, (2) lowest mean 
reductions of systolic blood pressure, and (3) lowest 
percentage reduction in DALYs per unit reduction in 
systolic blood pressure for which COBRA-BPS would 
remain cost-effective in each country, based on the 
common threshold of three times gross domestic product 
(GDP) per capita. We then present cost-effectiveness 
acceptability curves for each country, which we generated 
using TreeAge Pro 2019. These curves show the 
percentage of 1000 itera tions23 that exceed a given 
willingness-to-pay threshold that governments might 
consider as cost-effective when costs and the association 
between systolic blood pressure reductions and DALY 
improvements are fixed at the base-case levels and when 
the incremental improve ment in systolic blood pressure 
follows a normal distribution with mean and variance as 
estimated in the effectiveness analysis. Results of mean 
systolic blood pressure reductions are shown in the 
appendix (p 13). Lastly, we explore the implications of 
moving from a 3% to a 6% discount rate for costs.19 
Consistent with current recommendations, DALYs are 
not discounted.24
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Between April 1, 2016, and Feb 28, 2017, 11 510 individuals 
were screened and 2645 were enrolled and included 
in the study. Participants were examined between 
May 8, 2016, and March 31, 2019. We estimated that 
9·67 million individuals in Bangladesh, 5·62 million 
individuals in Pakistan, and 3·43 million individuals 
in Sri Lanka would be expected to screen positive 
for hypertension (appendix p 13). On the basis of these 
counts, 7·71 million (33%) of 23·47 million rural 
households in Bangladesh, 3·84 million (35%) of 
11·05 million rural households in Pakistan, and 
2·14 million (46%) of 4·61 million rural house holds in 
Sri Lanka would have at least one adult with hypertension 
and therefore receive home health education in year 1 of 
the scale-up (appendix p 13).
Table 1 presents the per-participant costs by cost 
category for the budget impact analysis. Per-participant 
costs were estimated to be US$10·65 for Bangladesh, 
$10·25 for Pakistan, and $6·42 for Sri Lanka.
Table 2 presents the per-participant (all rural people 
with hypertension aged 40 years or older) and per-capita 
(of national population) costs, eligible population counts, 
and total budget impact by country for the first 3 years of 
implementation; costs by activity are presented in the 
appendix (pp 6, 7). Cost estimation methodologies in first 
and subsequent years of scale-up can also be found in the 
appendix (pp 5, 6). In year 1 of scale-up, total budgetary 
impact costs are estimated to be $103·0 million in 
Bangladesh, $57·6 million in Pakistan, and $22·0 million 
in Sri Lanka to reach 9·67 million, 5·62 million, and 
3·43 million rural individuals with hypertension aged 
40 years or older, respectively. Based on national 
populations, per-capita costs are estimated to be $0·63 in 
Bangladesh, $0·29 in Pakistan, and $1·03 in Sri Lanka 
(table 2). Recurring per-participant costs in year 2 of 
scale-up are estimated to be $6·52 for Bangladesh, $5·70 
for Pakistan, and $6·03 for Sri Lanka, and in year 3 of 









Administration and oversight 1–5 $0·08 $0·49 $0·20
Training and implementation
Training of community health workers (standardised blood pressure monitoring and home 
health education)
1, 2 $4·61 $5·58 $0·33
Training of general practitioners  3 $0·12 $0·17 $0·07
Community health workers travel to households 1, 2 NA NA $0·27‡
Standardised blood pressure monitoring by community health workers 2 $3·06 $2·42 $1·18
Home health education 2 $2·74 $1·52 $2·59
Coordination at hypertension triage counter 4 $0·04 $0·08 $0·03
Provision of medication subsidies 5 NA NA $1·75
First-year cost per participant NA $10·65 $10·25 $6·42
NA=not applicable. *The numbered COBRA-BPS components are: (1) home health education by community health workers, (2) blood pressure monitoring and stepped-up 
referral to a trained general practitioner using a checklist, (3) training of public and private providers in management of hypertension and using a checklist, (4) designated 
hypertension triage reception and hypertension care coordinators in government clinics, and (5) a financing model to compensate for additional health services and provide 
subsidies to individuals with a low income and poorly controlled hypertension. More details can be found in the appendix (pp 5,6). †First-year costs per participant (reported 
as 2020 US$) were calculated by dividing total costs for the activity in the first year by the number of eligible participants with hypertension. ‡Stipend was given as a travel 
voucher for community health workers.
Table 1: First-year costs per participant by activity
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in Pakistan, and $5·92 in Sri Lanka. From year 1 to year 2 
of scale-up, estimated costs (total budget impact) reduced 
by 28% in Bangladesh and by 33% in Pakistan, whereas 
estimated costs increased by 3% in Sri Lanka; from year 1 
to year 3 of scale-up, estimated costs reduced by 24% in 
Bangladesh and by 31% in Pakistan, whereas costs 
increased by 10% in Sri Lanka. For years 2 and 3, 
estimated per-participant and per-capita costs decreased 
in Bangladesh and Pakistan mainly because of reduced 
training frequencies, as only refresher trainings were 
required. For Sri Lanka, although estimated training 
costs also decreased, an increase in the cost of medication 
subsidies led to a slight increase in total cost.
In our cost-effectiveness analysis, the mean age of 
participants in the trial was 57 years in Bangladesh and 
Pakistan and 63 years in Sri Lanka.10 Based on 
conditional life expectancies, participants are expected 
to live an average of 24 additional years in Bangladesh, 
22 additional years in Pakistan, and 21 additional 
years in Sri Lanka.25 The discounted present value 
of future intervention delivery costs for these durations 
was added to first-year costs to calculate the mean 
incremental cost. The health-care utilisation analysis 
(appendix pp 11, 12) reveals an overall increase in mean 
number of monthly antihypertensive medications 
of 0·11 (95% CI 0·04–0·18) at final follow-up (24 months 
after baseline), prompting us to assume that there is 
an increased use of antihypertensive medications. 
Although we did consider other differences in health-
care costs (appendix pp 11, 12), we found no other 
significant differences in costs between treatment and 
control groups, and therefore other costs were excluded 
from the analysis.
Using a methodical cost estimation of market prices of 
antihypertensive medicines in each country (as described 
in the appendix [pp 5, 6]), the per-participant lifetime 
incremental cost of scaling up COBRA-BPS was estimated 
to be $147 in Bangladesh, $136 in Pakistan, and $110 in 
Sri Lanka (appendix p 9). Based on the incremental costs 
(appendix p 8), the percentage of lifetime costs attributable 
to increased use of anti-hypertensive medication is 16% 
($221·29 million of $1·42 billion) in Bangladesh, 22% 
($165·20 million of $766·33 million) in Pakistan, and 
40% ($151·35 million of $377·97 million) in Sri Lanka, 
with differences driven by differential medication use 
rates and prices across countries.
The primary effectiveness analysis found that systolic 
blood pressure in rural communities decreased by a 
mean of 4·39 mm Hg (95% CI 7·84–0·94) in Bangladesh, 
4·99 mm Hg (9·63–0·35) in Pakistan, and 6·22 mm Hg 
(8·98–3·45) in Sri Lanka (table 3). Assuming that every 
1 mm Hg reduction in systolic blood pressure translates 
into a 2·2% reduction in cardiovascular disease 
DALYs,20–22 we multiplied the mean incremental reduction 
of systolic blood pressure in each country by 2·2% to 
estimate the percentage reduction in cardiovascular 
disease DALYs conferred by the COBRA-BPS programme. 
This reduced percentage of cardiovascular disease DALYs 
was then multiplied by cardiovascular disease DALYs 
borne by the eligible population to estimate the 
DALYs savings provided by the COBRA-BPS programme 
in each country. Dividing the costs by these savings 
yielded base-case incremental cost-effectiveness ratios of 
$3430 per DALY averted in Bangladesh, $2270 per DALY 
averted in Pakistan, and $4080 per DALY averted in 
Sri Lanka (table 3). Based on WHO-CHOICE thresholds 
of three times GDP per capita as a guide for what is cost-
effective,17,26 the base-case estimates (as seen in table 3) 
show COBRA-BPS to be cost-effective in all three 
countries.
The sensitivity analyses showed that, maintaining 
other parameters as constant values, COBRA-BPS would 
remain cost-effective at an incremental cost that was 
48% higher than the base case in Bangladesh, 97% higher 
than the base case in Pakistan, and 202% higher than the 
base case in Sri Lanka (appendix p 9). COBRA-BPS would 
also remain cost-effective if, all else being equal, mean 
incremental reductions of systolic blood pressure were no 
lower than 2·96 mm Hg in Bangladesh, 2·54 mm Hg 
in Pakistan, and 2·06 mm Hg in Sri Lanka, or if 
the percentage improvement in DALYs for each 1 unit 
decrease in systolic blood pressure remained above 
1·48% in Bangladesh, 1·12% in Pakistan, and 0·73% in 
Sri Lanka (appendix p 9). Using a 6% discount rate for 
costs instead of the 3% base rate,19 the cost-effectiveness 
ratio would improve to $2640 in Bangladesh, $1780 in 
Pakistan, and $3210 in Sri Lanka (appendix p 9).
The cost-effectiveness acceptability curves that are 
based on the probabilistic sensitivity analyses of 
1000 draws23 from the estimated distribution for systolic 
Year 1 Year 2 Year 3
Bangladesh (100% coverage)
Cost per participant $10·65 $6·52 $6·05
Cost per capita* $0·63 $0·45 $0·47
Eligible population† 9 671 504 11 391 650 13 009 795
Total budget impact*‡ $102 993 340 $74 294 630 $78 652 010
Pakistan (60% coverage)
Cost per participant $10·25 $5·70 $5·13
Cost per capita* $0·29 $0·19 $0·20
Eligible population† 5 619 670 6 728 994 7 796 449
Total budget impact‡ $57 610 060 $38 365 390 $40 021 640
Sri Lanka (100% coverage)
Cost per participant $6·42 $6·03 $5·92
Cost per capita* $1·03 $1·05 $1·10
Eligible population† 3 428 737 3 763 279 4 079 978
Total budget impact‡ $22 006 890 $22 675 410 $24 140 330
Data are 2020 US$ or n. Costs are rounded to the nearest $0·01 and the total budget impacts are rounded to the 
nearest $10. *Cost per capita is total cost divided by total national population count. †Individuals aged 40 years or 
older with hypertension in rural communities. ‡A breakdown of the cost types can be found in the appendix (pp 6, 7).
Table 2: Budget impact per participant and per capita from the health ministry perspective, in years 1–3 
of implementation
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blood pressure improvements, maintaining all other 
values as fixed, are shown in the appendix (pp 9, 10). 
These figures present the percentage of iterations that 
were predicted to be cost-effective for each willingness-
to-pay threshold that decision makers might consider. 
Applying the cost-effectiveness guidelines of WHO for 
Bangladesh ($5090), Pakistan ($4450), and Sri Lanka 
($12 310), COBRA-BPS was predicted to be cost-effective 
in 79·3% of iterations in Bangladesh, 85·2% of iterations 
in Pakistan, and 99·8% of iterations in Sri Lanka.
Discussion
In the multinational cohort in the PURE study, 
which included several low-income and middle-income 
countries, hypertension attributed the largest risk to 
cardiovascular diseases and death.27 This multi-country, 
cluster-randomised trial presents, to our knowledge, the 
first evidence that a customisable community-based 
intervention led by CHWs can be a cost-effective, scalable, 
and potentially sustainable solution for controlling blood 
pressure among those with hypertension in rural areas. 
Although countries use their own criteria for what is 
deemed cost-effective, COBRA-BPS was cost-effective 
for each of the three countries according to the WHO 
thresholds.
A primary reason for the cost-effectiveness of COBRA-
BPS is the relatively low per-participant cost. Scaling up 
COBRA-BPS would cost each country’s government 
less than $10·70 per participant in year 1, with 
comprehensive training being responsible for roughly 
half of the costs. In subsequent years, costs are expected 
to decrease as only refresher trainings are required for 
existing CHWs. However, if countries need to scale up 
the number of CHWs, as might be the case for Sri Lanka 
given the low number of CHWs per capita, then training 
costs would increase. Sri Lanka is also the only country 
where the government pays for medications, and 
medication subsidies are responsible for 27% of their 
per-participant costs.
When considering per-capita costs across the entire 
population of each country, as opposed to per-participant 
costs, the costs were estimated at less than $1 per year in 
Bangladesh and Pakistan, and less than $1·20 per year in 
Sri Lanka. Differences in costs across countries result 
from differences in the number of CHWs required to be 
trained, differences in training costs, and differences in 
implementation design, staffing models, wage rates, 
and hypertension prevalence, as greater hypertension 
prevalence reduces the average fixed cost of the pro-
gramme by spreading it across more individuals.
Although previous hypertension trials from low-
income and middle-income countries have also shown 
cost-effectiveness based on similar cost-effectiveness 
analysis thresholds,28 COBRA-BPS is unique with its 
focus on rural populations, integration of all components 
into the existing health-care infrastructure, and reliance 
on government CHWs to proactively conduct blood 
pressure monitoring and health promotion activities. 
Leveraging this infrastructure contributed substantially 
to the low costs of programme delivery regardless of 
differences in programme implementation, hypertension 
prevalence, and underlying cost structures. Therefore, 
our results are likely to be generalisable to many low-
income and middle-income countries that rely on CHWs.
Given our budget impact projections and current 
health budgets of $6·00 per capita in Bangladesh, 
$14·00 per capita in Pakistan, and $69·00 per capita in 
Sri Lanka,17 the benefits of COBRA-BPS could be achieved 
with a health budget increase of 10% in Bangladesh, 
3% in Pakistan, and 2% in Sri Lanka in the first year and 
slightly less in subsequent years in Bangladesh and 
Pakistan (but slightly more in Sri Lanka due to greater 
cost of medications). Although affordability is always a 
concern, these cost increases are not substantially greater 
than other “best buy” interventions recommend by 
WHO.29
This study has many strengths, including a standardised 
intervention, a rigorous multi-country effectiveness 
evaluation, and prospective cost data collection. Yet there 
are limitations. One limitation for the cost-effectiveness 
analyses is that the cost-effectiveness ratios are based on 
an algorithm that directly converts blood pressure reduc-
tions to DALYs averted. Although we use conservative 
assumptions for this relationship and did sensitivity 
Bangladesh (100% coverage) Pakistan (60% coverage) Sri Lanka (100% coverage)
Total incremental cost for cost-effectiveness analysis (US$)* $1 421 174 180 $766 327 830 $377 973 350
Mean incremental reduction of systolic blood pressure (mm Hg)10 4·39 (7·84–0·94) 4·99 (9·63–0·35) 6·22 (8·98–3·45)
Cardiovascular disease DALYs borne by eligible population (n)† 4 285 514 3 082 505 676 600
Avertable cardiovascular disease DALYs (n)‡ 413 895 338 397 92 586
Incremental cost per cardiovascular disease DALY averted (US$) $3430 $2270 $4080
WHO threshold for being cost-effective (US$)§ $5090 $4450 $12 310
Gross domestic product per capita17 $1560 $1460 $4080
Data are n, mm Hg (95% CI), or 2020 US$. Monetary values are rounded to the nearest $10. DALY=disability-adjusted life-year. *A breakdown of the cost types can be found in the appendix (p 8). †Individuals 
aged 40 years or older with hypertension in rural communities. ‡Based on an estimated 2·2% reduction in cardiovascular disease DALYs per 1 mm Hg reduction in systolic blood pressure. §Threshold for being 
cost-effective set for at least three times gross domestic product per capita of each country.17,26
Table 3: Cost-effectiveness of COBRA-BPS from the health systems perspective
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analyses to measure the influence of our assumptions on 
results, additional studies should be done to find out 
whether this relationship holds over longer time periods. 
The analyses also assumed no differences in long-
term health-care utilisation across study groups. This 
assumption is probably conservative as a successful 
intervention should result in fewer cardiovascular disease 
events. The analyses also assume that the benefits of 
blood pressure reduction and the relationship of blood 
pressure reduction with improvement in DALYs would 
continue throughout the participants’ lifetime. As some of 
the improvements in systolic blood pressure resulted 
from overall increased use of medications, both our 
cost and cost-effectiveness estimates would be inflated if 
usage decreased with time. Consistent with the latest 
recommendations, we also did not discount DALYs.24 
Discounting DALYs would reduce the cost-effectiveness 
ratios to unknown degrees as the timing of future 
cardiovascular disease events is unknown. We also did not 
measure the effect of COBRA-BPS on the existing duties 
of CHWs, which include maternal and child health 
services. However, the funds for additional work were 
channelled through the district office in each country with 
the flexibility to hire additional workers if needed. Thus, 
we assume the benefits of COBRA-BPS did not come at 
the expense of other programmes. Finally, we limit the 
benefits of COBRA-BPS to benefits caused by reductions 
in blood pressure. However, our inter vention, which also 
focuses on nutrition, tobacco cessation, and physical 
activity, probably has other benefits that expand beyond 
blood pressure improvements.
The programme could be further strengthened by 
including other components, such as risk factor reduc-
tions for diabetes or other chronic diseases, additional 
medication subsidies, or even universal health coverage, 
as out-of-pocket costs remain a barrier to access to 
medications and health services in Bangladesh, Pakistan, 
and Sri Lanka, as well as other countries.2
In summary, this study presents robust evidence for a 
cost-effective multicomponent programme led by CHWs, 
namely, COBRA-BPS, for the management of hyper-
tension in rural communities. The programme’s low cost 
and high scalability suggest that it presents a viable 
strategy for responding to the growing cardiovascular 
disease epidemic in rural communities in low-income 
and middle-income countries currently served by CHWs 
and should qualify as a priority intervention in the 
targeted countries and possibly many other countries.
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